Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Globe Newswire•10/08/2026•03:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
